{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:14:39Z","timestamp":1792239279609,"version":"4.4.0"},"reference-count":149,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Histone deacetylases (HDACs) are pivotal epigenetic regulators that control gene expression, cell proliferation, and differentiation, and their dysregulation is closely associated with the onset and progression of multiple cancers. The therapeutic importance of these enzymes is reflected by FDA approval of HDAC inhibitors for oncology indications. Despite this clinical success, most FDA-approved agents employ conventional zinc-binding groups (ZBGs) such as hydroxamic acid and 2-aminoanilide, which are frequently linked to metabolic instability, genotoxicity, and poor pharmacokinetic behavior. These limitations have spurred the development of structurally diverse and safer HDAC inhibitors incorporating alternative ZBGs. This review provides a comprehensive analysis of recently developed HDAC inhibitors reported in the last few years, emphasizing their structure\u2013activity relationships (SARs), chemical scaffolds, and binding features\u2014including cap, linker, and ZBG motifs. Both hydroxamate-based and non-hydroxamate inhibitors, such as benzamides, hydrazides, and thiol-containing analogs, are critically evaluated. Moreover, the potency and selectivity profiles of these inhibitors are summarized across different cancer and normal cell lines, as well as specific HDAC isoforms, providing a clearer understanding of their therapeutic potential. Emerging dual-target HDAC inhibitors, such as HDAC\u2013tubulin, HDAC\u2013PI3K and HDAC\u2013CDK hybrids, are also discussed for their synergistic anticancer effects.<\/jats:p>","DOI":"10.3390\/cells14241997","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:52:59Z","timestamp":1765813979000},"page":"1997","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-9700","authenticated-orcid":false,"given":"Mohammed","family":"Hawash","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, An-Najah National University, Nablus 00433, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/ajio.ajio_3_25","article-title":"Advancing anticancer drug development: Overcoming challenges and exploring new therapeutic strategies","volume":"2","author":"Sharma","year":"2025","journal-title":"Ayush J. Integr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: A comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/1061186X.2024.2424895","article-title":"Overcoming antibiotic resistance: The potential and pitfalls of drug repurposing","volume":"33","author":"Abavisani","year":"2025","journal-title":"J. Drug Target."},{"key":"ref_4","first-page":"762","article-title":"Drugging the \u2018undruggable\u2019KRAS: Breakthroughs, challenges, and opportunities in pancreatic cancer","volume":"22","author":"Khan","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Patrick, G.L. (2023). An Introduction to Medicinal Chemistry, Oxford University Press. [7th ed.].","DOI":"10.1093\/hesc\/9780198866664.001.0001"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tran, C., and Hamze, A. (2025). Recent Advancements in the Development of HDAC\/Tubulin Dual-Targeting Inhibitors. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030341"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/a-0898-7347","article-title":"Highlights on Specific Biological Targets; Cyclin-Dependent Kinases, Epidermal Growth Factor Receptors, Ras Protein, and Cancer Stem Cells in Anticancer Drug Development","volume":"69","author":"Hawash","year":"2019","journal-title":"Drug Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"120946","DOI":"10.1016\/j.lfs.2022.120946","article-title":"Current trends in development of HDAC-based chemotherapeutics","volume":"308","author":"Cheshmazar","year":"2022","journal-title":"Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Talom, A., Barhoi, A., Jirpu, T., Dawn, B., and Ghosh, A. (2025). Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment. Clin. Transl. Oncol., 1\u201315.","DOI":"10.1007\/s12094-025-03995-x"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737140.2025.2458156","article-title":"Synergistic strategies: Histone deacetylase inhibitors and platinum-based drugs in cancer therapy","volume":"25","author":"Shirbhate","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez-Cantudo, L., Ramos, A., Coderch, C., and de Pascual-Teresa, B. (2021). Proteasomal degradation of Zn-dependent Hdacs: The E3-ligases implicated and the designed protacs that enable degradation. Molecules, 26.","DOI":"10.3390\/molecules26185606"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.chembiol.2023.11.009","article-title":"A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cells","volume":"30","author":"Peterson","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1568009623666230801094826","article-title":"Elucidation of the role of the epigenetic regulatory mechanisms of PI3K\/Akt\/mTOR signaling pathway in human malignancies","volume":"24","author":"Mohite","year":"2024","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/rej.2015.1717","article-title":"Role of the cell cycle re-initiation in DNA damage response of post-mitotic cells and its implication in the pathogenesis of neurodegenerative diseases","volume":"19","author":"Tokarz","year":"2016","journal-title":"Rejuvenation Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pu, J. (2025). The Role of Histone Deacetylase (HDAC) Inhibitors and Cytokine-Induced Killer Cell (CIK) in Multiple Myeloma. [Ph.D. Thesis, Universit\u00e4ts-und Landesbibliothek Bonn].","DOI":"10.1002\/cti2.1500"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17460441.2021.1877656","article-title":"An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives","volume":"16","author":"Su","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Theodoropoulou, M.A., Mantzourani, C., and Kokotos, G. (2024). Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases. Biomolecules, 14.","DOI":"10.3390\/biom14121605"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33307","DOI":"10.1038\/s41598-025-02774-6","article-title":"Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics","volume":"15","author":"Tarawneh","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","article-title":"Multiple roles of class I HDACs in proliferation, differentiation, and development","volume":"69","author":"Reichert","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, H., Zhan, Z., Gan, L., and Bai, O. (2025). Mechanisms of HDACs in cancer development. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1529239"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","article-title":"Recent progress in histone deacetylase inhibitors as anticancer agents","volume":"27","author":"Cappellacci","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e202405484","DOI":"10.1002\/slct.202405484","article-title":"Clinical Applications of HDAC Inhibitors as Anticancer Agents in Prostate, Breast, Ovarian, and Cervical Cancers","volume":"10","author":"Bakrim","year":"2025","journal-title":"ChemistrySelect"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ruzic, D., Djokovi\u0107, N., Srdi\u0107-Raji\u0107, T., Echeverria, C., Nikolic, K., and Santibanez, J.F. (2022). Targeting histone deacetylases: Opportunities for cancer treatment and chemoprevention. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010209"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2300536","DOI":"10.1002\/ardp.202300536","article-title":"Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells","volume":"357","author":"Abdelsalam","year":"2024","journal-title":"Arch. Pharm."},{"key":"ref_25","first-page":"22","article-title":"HDAC as a cancer target: Various scaffolds based on HDAC inhibitors and an overview of their advances","volume":"5","author":"Abdelraheem","year":"2024","journal-title":"Octahedron Drug Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.53388\/PD202505008","article-title":"Recent progress of small molecular HDAC modulators for cancer therapy and beyond","volume":"5","author":"Zhao","year":"2025","journal-title":"Pharmacol. Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-025-00788-w","article-title":"Epigenetic regulation of histone modifications in glioblastoma: Recent advances and therapeutic insights","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Morales-Herrej\u00f3n, G., Garc\u00eda-V\u00e1zquez, J.B., Fern\u00e1ndez-Pomares, C., Bakalara, N., Correa-Basurto, J., and Mendoza-Figueroa, H.L. (2025). Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on N-Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030351"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The zinc-binding group effect: Lessons from non-hydroxamic acid vorinostat analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","article-title":"Adverse drug reaction profiles of histone deacetylase inhibitors","volume":"15","author":"Begum","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Inoue, Y., and Yasunaga, J.-I. (2025). Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas. Cells, 14.","DOI":"10.3390\/cells14171306"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gui, L., Xie, Z., Qin, Y., Liu, P., Yang, J., Chen, X., Li, Z., Tao, R., and Shi, Y. (2025). Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed\/refractory B cell non-Hodgkin lymphoma: A Phase 1 study. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14370-y"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/phar.1671","article-title":"Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat","volume":"35","author":"Afifi","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1310\/hpj4911-1009","article-title":"Drug monographs: Belinostat and idelalisib","volume":"49","author":"Piper","year":"2014","journal-title":"Hosp. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4274\/tjps.75047","article-title":"Histone deacetylase inhibitors: A prospect in drug discovery","volume":"16","author":"Yadav","year":"2018","journal-title":"Turk. J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10637-015-0321-8","article-title":"Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies","volume":"34","author":"Calvo","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/cas.13062","article-title":"Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies","volume":"107","author":"Imai","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat","volume":"57","author":"Westerman","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus, A. (2025). Histone deacetylase inhibition with givinostat: A multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1514898"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: First approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17425255.2023.2219839","article-title":"Population pharmacokinetic\u2013pharmacodynamic analysis of givinostat","volume":"19","author":"Fiorentini","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.curtheres.2025.100787","article-title":"Unleashing the Potential of Givinostat: A Novel Therapy for Duchenne Muscular Dystrophy","volume":"102","author":"Anjum","year":"2025","journal-title":"Curr. Ther. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.63785\/cpr.2025.1.3.308322","article-title":"Duvyzat (Givinostat) in Duchenne Muscular Dystrophy: Mechanisms, Clinical Impact, and Future Directions","volume":"1","author":"Kumar","year":"2025","journal-title":"Curr. Pharm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Galluzzi, L., and Spada, S. (2025). Epigenetic Regulation of Cancer-Part D, Academic Press.","DOI":"10.1016\/S1937-6448(25)00015-2"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00109-025-02532-1","article-title":"Mechanism and application of HDAC inhibitors in the treatment of hepatocellular carcinoma","volume":"103","author":"Hao","year":"2025","journal-title":"J. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Pires, G.S., Tolomeu, H.V., Rodrigues, D.A., Lima, L.M., Fraga, C.A.M., and Pinheiro, P.d.S.M. (2025). Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups. Pharmaceuticals, 18.","DOI":"10.20944\/preprints202503.2208.v1"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/13543776.2025.2516785","article-title":"An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020\u2013present): Part 2-patent published","volume":"35","author":"Shukla","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s13721-025-00589-z","article-title":"Decoding HDACs and its inhibitors-artificial intelligence assisted smart software based super computational modelling technology in targeting cancer and neurological disorders of the brain","volume":"14","author":"Rizwan","year":"2025","journal-title":"Netw. Model. Anal. Health Inform. Bioinform."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Al Rahim, N.A.A., Mahmood, A.A.R., Tahtamouni, L.H., Bawadi, R.M., Almasri, A.Y., Hamad, M.A., Hussein, N.A., Yasin, S.R., and Saleh, A.M. (2025). Synthesis, In Silico, and Biological Evaluation of Non-Hydroxamate Benzoic Acid\u2013Based Derivatives as Potential Histone Deacetylase Inhibitors (HDACi). Chem. Biodivers., e01492.","DOI":"10.1002\/cbdv.202501492"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"110695","DOI":"10.1016\/j.compbiomed.2025.110695","article-title":"In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitors","volume":"196","author":"Baselious","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18216","DOI":"10.1021\/acs.jmedchem.5c00479","article-title":"Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group Modifications","volume":"68","author":"Olaoye","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ganesan, A. (2020). Targeting the zinc-dependent histone deacetylases (HDACs) for drug discovery. Chemical Epigenetics, Springer.","DOI":"10.1007\/7355_2019_68"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Spallotta, F., and Illi, B. (2024). The role of HDAC6 in glioblastoma multiforme: A new avenue to therapeutic interventions?. Biomedicines, 12.","DOI":"10.3390\/biomedicines12112631"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.2174\/0929867328666210629160647","article-title":"Targeting class IIa HDACs: Insights from phenotypes and inhibitors","volume":"28","author":"Liu","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"108231","DOI":"10.1016\/j.bioorg.2025.108231","article-title":"New indolin-2-ones, possessing sunitinib scaffold as HDAC inhibitors and anti-cancer agents with potential VEGFR inhibition activity; design, synthesis and biological evaluation","volume":"156","author":"Yousefian","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"117634","DOI":"10.1016\/j.ejmech.2025.117634","article-title":"Challenging triple negative breast cancer through HDAC6 selective inhibition: Novel cap-group identification, structure-activity relationships, computational and biological studies","volume":"292","author":"Barone","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2174\/0929867329666220922105615","article-title":"Multi-targeted HDAC inhibitors as anticancer agents: Current status and future prospective","volume":"30","author":"Patel","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/bloodadvances.2020003566","article-title":"Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors","volume":"5","author":"Mensah","year":"2021","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"107480","DOI":"10.1016\/j.leukres.2024.107480","article-title":"Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study","volume":"140","author":"Kazmierczak","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","article-title":"First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors","volume":"19","author":"Brunetto","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_64","unstructured":"Clinicaltrials.gov (2025, November 26). NCT02953301, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02953301#publications."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"20406207251371298","DOI":"10.1177\/20406207251371298","article-title":"Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R \u2265 3.5 in patients aged 60 or older: Current landscape and challenges","volume":"16","author":"Hou","year":"2025","journal-title":"Ther. Adv. Hematol."},{"key":"ref_66","unstructured":"Clinicaltrials.gov (2025, November 26). NCT03151408, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03151408?intr=pracinostat&term=NCT03151408&rank=1."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Tian, J., Han, M., Song, F., Liu, Y., Shen, Y., and Zhong, J. (2025). Advances of HDAC inhibitors in tumor therapy: Potential applications through immune modulation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1576781"},{"key":"ref_68","unstructured":"Clinicaltrials.gov (2025, November 28). NCT03618602, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03618602?intr=Bisthianostat&rank=1."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bcp.15997","article-title":"Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG-750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG-745)","volume":"90","author":"Kim","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_70","unstructured":"Clinicaltrials.gov (2025, November 28). NCT05249101, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05249101?intr=Ivaltinostat&rank=1."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-0312","article-title":"A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors","volume":"19","author":"Venugopal","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_72","unstructured":"Asad, M. (2025). Exploiting Epigenetic Pathway to Target Colorectal Cancer Stemness. [Ph.D. Thesis, Oklahoma State University]."},{"key":"ref_73","unstructured":"Clinicaltrials.gov (2025, November 27). NCT01486277, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01486277?intr=Quisinostat&term=NCT01486277&rank=1."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41420-025-02470-4","article-title":"The dual HDAC\/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma","volume":"11","author":"Gou","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yang, C., Ren, X., Cui, Y., Jiang, H., Li, M., Yu, K., Shen, S., Li, M., Zhang, X., and Zhao, X. (2025). New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1438001"},{"key":"ref_76","unstructured":"Clinicaltrials.gov (2025, November 27). NCT01742988, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01742988?intr=CUDC-907&term=NCT01742988&rank=1."},{"key":"ref_77","unstructured":"Ravikumar, B., Cicho\u0144ska, A., Sahni, N., Aittokallio, T., and Rahman, R. (2025). Advancements in Rational Multi-Targeted Drug Discovery: Improving the Efficacy-Safety Balance of Small Molecule Cancer Therapeutics. Polypharmacology: Strategies for Multi-Target Drug Discovery, John Wiley & Sons Inc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10616-025-00726-6","article-title":"Cell culture in salivary gland tumor research: Molecular insights of pathogenic targets and personalized medicine","volume":"77","author":"Lavareze","year":"2025","journal-title":"Cytotechnology"},{"key":"ref_79","unstructured":"Clinicaltrials.gov (2025, November 27). NCT01384799, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01384799?intr=cudc%20101&rank=4."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e10710","DOI":"10.1002\/btm2.10710","article-title":"Targeting the epigenome with advanced delivery strategies for epigenetic modulators","volume":"10","author":"Guha","year":"2025","journal-title":"Bioeng. Transl. Med."},{"key":"ref_81","unstructured":"Clinicaltrials.gov (2025, November 27). NCT00697879, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00697879?intr=CHR%203996&rank=2."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Rembia\u0142kowska, N., Rekiel, K., Urbanowicz, P., Mamala, M., Marczuk, K., Wojtaszek, M., \u017bywica, M., Radzevi\u010di\u016bt\u0117-Val\u010diuk\u0117, E., Novickij, V., and Kulbacka, J. (2025). Epigenetic dysregulation in cancer: Implications for gene expression and DNA repair-associated pathways. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136531"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e15137","DOI":"10.1200\/JCO.2023.41.16_suppl.e15137","article-title":"Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors","volume":"41","author":"Lin","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"28866","DOI":"10.1038\/s41598-025-12194-1","article-title":"The effect of coadministration of D156844 and AR42 (REC-2282) on the survival and motor phenotype of mice with spinal muscular atrophy","volume":"15","author":"Harris","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_85","unstructured":"Clinicaltrials.gov (2025, November 27). NCT05130866, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05130866?intr=REC-2282%20&rank=1."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejmech.2018.12.039","article-title":"Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview","volume":"164","author":"Banerjee","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_87","unstructured":"Clinicaltrials.gov (2025, November 28). NCT00677001, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00677001?intr=R-306465&rank=1."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.jmedchem.0c01967","article-title":"HDAC7 inhibition by phenacetyl and phenylbenzoyl hydroxamates","volume":"64","author":"Mak","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1111\/febs.70062","article-title":"Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors","volume":"292","author":"Borrello","year":"2025","journal-title":"FEBS J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.molpha.2025.100062","article-title":"Design and evaluation of highly selective HDAC6 inhibitors derived from the natural product tryptoline","volume":"107","author":"Ali","year":"2025","journal-title":"Mol. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"109085","DOI":"10.1016\/j.bioorg.2025.109085","article-title":"New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells","volume":"166","author":"Cursaro","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12762","DOI":"10.1039\/D4RA01672F","article-title":"Design, synthesis and antiproliferative evaluation of tetrahydro-\u03b2-carboline histone deacetylase inhibitors bearing an aliphatic chain linker","volume":"14","author":"Shi","year":"2024","journal-title":"RSC Adv."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Saul, J.G., Huckleby, A.E., Gugello, M.C., Urbanczyk, J., Desmarais, S., Shin, H., Bokka, A., Jeon, J., Tripathy, J.N., and Kim, S.-K. (2025). Inhibitory Effect of Novel Dihydroxamate Derivatives for Histone Deacetylase 1. Front. Biosci. Sch., 17.","DOI":"10.31083\/FBS38998"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e2400889","DOI":"10.1002\/ardp.202400889","article-title":"New potent N-hydroxycinnamamide-based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP-1 leukaemia cells","volume":"358","author":"Onuscakova","year":"2025","journal-title":"Arch. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"111777","DOI":"10.1016\/j.cbi.2025.111777","article-title":"The novel selective HDAC1 inhibitor ZJH-1 exhibits potent antitumor activity in castration-resistant prostate cancer, potentially involving HSP90AA1","volume":"421","author":"Bao","year":"2025","journal-title":"Chem.-Biol. Interact."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/14756366.2020.1835883","article-title":"Identification of histone deacetylase inhibitors with (arylidene) aminoxy scaffold active in uveal melanoma cell lines","volume":"36","author":"Nencetti","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"24589","DOI":"10.1038\/s41598-025-08474-5","article-title":"Design and synthesis of thiazole-based hydroxamate histone deacetylase inhibitors with potent antitumor efficacy by inducing apoptosis, pyroptosis and cell cycle arrest","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"129986","DOI":"10.1016\/j.bmcl.2024.129986","article-title":"Design and optimization of novel Tetrahydro-\u03b2-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis","volume":"114","author":"Fan","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"104728","DOI":"10.1016\/j.bioorg.2021.104728","article-title":"Synthesis of nigranoic acid and manwuweizic acid derivatives as HDAC inhibitors and anti-inflammatory agents","volume":"109","author":"Ni","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12964-024-01733-4","article-title":"Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy","volume":"22","author":"Zhu","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/14756366.2020.1839446","article-title":"Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms","volume":"36","author":"Mehndiratta","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"108879","DOI":"10.1016\/j.bioorg.2025.108879","article-title":"Novel imidazolyl-hydroxamic acid Schiff base scaffold derivatives as histone deacetylase inhibitors: Design, synthesis, and biological assessment","volume":"164","author":"Jamshidi","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e202300238","DOI":"10.1002\/cbic.202300238","article-title":"Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors","volume":"24","author":"Zhou","year":"2023","journal-title":"Chembiochem A Eur. J. Chem. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Shirbhate, E., Koch, B., Singh, V., Dubey, A., Yasin, H.K.A., and Rajak, H. (2025). Heteroaryl-Capped Hydroxamic Acid Derivatives with Varied Linkers: Synthesis and Anticancer Evaluation with Various Apoptosis Analyses in Breast Cancer Cells, Including Docking, Simulation, DFT, and ADMET Studies. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081148"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"8486","DOI":"10.1021\/acs.jmedchem.1c00420","article-title":"Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia","volume":"64","author":"Toutah","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"115776","DOI":"10.1016\/j.ejmech.2023.115776","article-title":"Tetrahydro-\u03b2-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity","volume":"260","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"106867","DOI":"10.1016\/j.jsbmb.2025.106867","article-title":"Design, synthesis, and biological evaluation of estratriene-based hydroxamic acid derivatives as histone deacetylase inhibitors","volume":"255","author":"Chen","year":"2025","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Neganova, M., Aleksandrova, Y., Suslov, E., Mozhaitsev, E., Munkuev, A., Tsypyshev, D., Chicheva, M., Rogachev, A., Sukocheva, O., and Volcho, K. (2021). Novel Multitarget Hydroxamic Acids with a Natural Origin CAP Group against Alzheimer\u2019s Disease: Synthesis, Docking and Biological Evaluation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111893"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"B\u00fclb\u00fcl, E.F., Melesina, J., Ibrahim, H.S., Abdelsalam, M., Vecchio, A., Robaa, D., Zessin, M., Schutkowski, M., and Sippl, W. (2022). Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors. Molecules, 27.","DOI":"10.3390\/molecules27082526"},{"key":"ref_110","first-page":"e-20250121","article-title":"Synthesis, Molecular Docking, Dynamics Analysis Studies, and Cytotoxicityactivity Evaluation of Novel Berberine Derivative Bearing Oxadiazole and O-Diaminobenzene Moieties","volume":"48","author":"Jiang","year":"2025","journal-title":"Qu\u00edmica Nova"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1021\/acs.jnatprod.4c00913","article-title":"Synthesis and Evaluation of 9-epi-Koshidacin B as Selective Inhibitor of Histone Deacetylase 1","volume":"87","author":"Ghosh","year":"2024","journal-title":"J. Nat. Prod."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1038\/s41467-021-23609-8","article-title":"Anchor extension: A structure-guided approach to design cyclic peptides targeting enzyme active sites","volume":"12","author":"Hosseinzadeh","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"108154","DOI":"10.1016\/j.compbiolchem.2024.108154","article-title":"Exploring potential molecular targets and therapeutic efficacy of beauvericin in triple-negative breast cancer cells","volume":"112","author":"Patra","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/0115734064320232240709105228","article-title":"Crucial Structural Understanding for Selective HDAC8 Inhibition: Common Pharmacophores, Molecular Docking, Molecular Dynamics, and Zinc Binder Analysis of Selective HDAC8 Inhibitors","volume":"21","author":"Sarkar","year":"2025","journal-title":"Med. Chem."},{"key":"ref_115","first-page":"514","article-title":"Molecular docking, synthesis, characteristics and preliminary cytotoxic study of new coumarin-sulfonamide derivatives as histone deacetylase inhibitors","volume":"77","author":"Alibeg","year":"2024","journal-title":"Pol. Med. Bibliogr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1021\/acs.jmedchem.4c00541","article-title":"Hydrazides as inhibitors of histone deacetylases","volume":"67","author":"Carreiras","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_117","first-page":"1201","article-title":"In Silico Profiling of New 1,2,3,4-Tetrahydropyrimidine Derivatives Linked to Hydroxamate Moiety by Various Aromatic Linkers as HDACs Inhibitors","volume":"8","author":"Alwash","year":"2025","journal-title":"Adv. J. Chem. Sect. A"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1002\/mog2.59","article-title":"Epigenetic regulation in cancer therapy: From mechanisms to clinical advances","volume":"3","author":"Tao","year":"2024","journal-title":"MedComm\u2013Oncology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-025-01844-w","article-title":"Epigenetic marvels: Exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies","volume":"17","author":"Tahghighi","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Villegas-Vazquez, E.Y., Mar\u00edn-Carrasco, F.P., Reyes-Hern\u00e1ndez, O.D., B\u00e1ez-Gonz\u00e1lez, A.S., Bustamante-Montes, L.P., Padilla-Benavides, T., Quintas-Granados, L.I., and Figueroa-Gonz\u00e1lez, G. (2025). Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1514120"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00432-024-05615-7","article-title":"Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K\/AKT\/mTOR pathway","volume":"150","author":"Wu","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/10428194.2024.2328227","article-title":"Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1\/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma","volume":"65","author":"Li","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-022-01915-2","article-title":"Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy","volume":"57","author":"Kawakubo","year":"2022","journal-title":"J. Gastroenterol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14656566.2023.2219392","article-title":"Advances in Hodgkin\u2019s lymphoma pharmacotherapy: A focus on histone deacetylase inhibitors","volume":"24","author":"Ho","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s42003-023-04485-y","article-title":"The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity","volume":"6","author":"Liu","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_127","unstructured":"Clinicaltrials.gov (2025, November 28). NCT01977638, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01977638?intr=CXD101&rank=1#publications."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ibrahim, H.S., Abdelsalam, M., Zeyn, Y., Zessin, M., Mustafa, A.M., Fischer, M.A., Zeyen, P., Sun, P., B\u00fclb\u00fcl, E.F., and Vecchio, A. (2021). Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010369"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"105461","DOI":"10.1016\/j.bioorg.2021.105461","article-title":"\u03b2-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies","volume":"117","author":"Namballa","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"117636","DOI":"10.1016\/j.ejmech.2025.117636","article-title":"Design and synthesis of pyridine-based benzamides as potent HDAC3 inhibitors as an armament against breast cancer with in vivo validation","volume":"291","author":"Himaja","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cbdd.14055","article-title":"Synthesis and structure-activity relationship of thiol-based histone deacetylase 6 inhibitors","volume":"100","author":"Guo","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"108348","DOI":"10.1016\/j.bioorg.2025.108348","article-title":"Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs)","volume":"159","author":"Song","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s00044-025-03418-0","article-title":"Exploring putative histone deacetylase inhibitors with antiproliferative activity of chrysin derivatives","volume":"34","author":"Kamloon","year":"2025","journal-title":"Med. Chem. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"106921","DOI":"10.1016\/j.ejps.2024.106921","article-title":"Discovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity","volume":"203","author":"Cho","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: Role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"19590","DOI":"10.1038\/s41598-025-04714-w","article-title":"The hydroxamate based HDAC inhibitor WMJ-J-09 induces colorectal cancer cell death by targeting tubulin and downregulating survivin","volume":"15","author":"Huang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ibrahim, T.S., Malebari, A.M., and Mohamed, M.F. (2021). Design, synthesis, in vitro anticancer evaluation and molecular modelling studies of 3, 4, 5-trimethoxyphenyl-based derivatives as dual EGFR\/HDAC hybrid inhibitors. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111177"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"116454","DOI":"10.1016\/j.bmc.2021.116454","article-title":"Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2","volume":"50","author":"Lee","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"107556","DOI":"10.1016\/j.bioorg.2024.107556","article-title":"Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors","volume":"151","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"105564","DOI":"10.1016\/j.bioorg.2021.105564","article-title":"Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase\/HDAC inhibitors","volume":"119","author":"Bass","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"116301","DOI":"10.1016\/j.ejmech.2024.116301","article-title":"Design and biological evaluation of dual tubulin\/HDAC inhibitors based on millepachine for treatment of prostate cancer","volume":"268","author":"Xie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"107284","DOI":"10.1016\/j.bioorg.2024.107284","article-title":"Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio) Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study","volume":"146","author":"Abdulwahab","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"114058","DOI":"10.1016\/j.ejmech.2021.114058","article-title":"Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40199-024-00514-1","article-title":"Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases\/ribonucleotide reductase inhibitor with antitumor activities","volume":"32","author":"Shetty","year":"2024","journal-title":"Daru J. Pharm."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"107964","DOI":"10.1016\/j.bioorg.2024.107964","article-title":"Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies","volume":"153","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Zhang, S., Wang, Y.F., Lu, H.R., Yang, X.Q., Zhang, Y., Ma, X.L., and Huang, R.Z. (2025). Discovery of Novel Imidazothiazole-Based Hydroxamic Acid Derivatives as Potent Indoleamine 2,3-Dioxygenase 1 and Histone Deacetylase 6 Dual Inhibitors. Molecules, 30.","DOI":"10.3390\/molecules30122508"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"108577","DOI":"10.1016\/j.bioorg.2025.108577","article-title":"Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl-pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment","volume":"162","author":"Chen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"117658","DOI":"10.1016\/j.ejmech.2025.117658","article-title":"Discovery of hydrazide-based PI3K\/HDAC dual inhibitors with enhanced pro-apoptotic activity in lymphoma cells","volume":"292","author":"Hou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"118192","DOI":"10.1016\/j.ejmech.2025.118192","article-title":"Design and synthesis of novel cyclin-dependent kinase 4\/6 (CDK4\/6) and histone deacetylase (HDAC) dual inhibitors: In vitro and in vivo anticancer activity","volume":"301","author":"Kim","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/24\/1997\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:13:20Z","timestamp":1766034800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/24\/1997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":149,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cells14241997"],"URL":"https:\/\/doi.org\/10.3390\/cells14241997","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}